Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Stifel Maintains Hold on Wayfair, Lowers Price Target to $55

Stifel Maintains Hold on Wayfair, Lowers Price Target to $55

Stifel analyst Scott Devitt maintains Wayfair (NYSE:W) with a Hold and lowers the price target from $60 to $55.

byBenzinga Newsdesk

July 15, 2022

1 minute read

Stifel analyst Scott Devitt maintains Wayfair (NYSE:W) with a Hold and lowers the price target from $60 to $55.

Toyota’s Market Value Plunges Over $15B Amid Test Falsification Scandal; Mazda, Honda, Suzuki Follow Suit

By Benzinga Neuro

June 10, 1:38 AM

The stock prices of major Japanese automakers, including Toyota, Mazda, Honda, and Suzuki, have taken a hit following a safety scandal.

APIE

A Look Into Marsh & McLennan Inc’s Price Over Earnings

By Benzinga Insights

June 11, 10:15 AM

In the current market session, Marsh & McLennan Inc. (NYSE:MMC) stock price is at $208.58, after a 0.49%…

MMC

Analyst Ratings

Analyst Expectations for Howmet Aerospace’s Future

By Benzinga Insights

July 25, 10:00 AM

Within the last quarter, Howmet Aerospace (NYSE:HWM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

HWM

FDA Approves First Redosable Gene Therapy, Krystal Biotech’s Treatment For Skin Blistering Disorder

By Vandana Singh

May 22, 8:06 AM

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic

KRYS

Stifel Maintains Hold on Wayfair, Lowers Price Target to $55

Related Posts

Toyota’s Market Value Plunges Over $15B Amid Test Falsification Scandal; Mazda, Honda, Suzuki Follow Suit

A Look Into Marsh & McLennan Inc’s Price Over Earnings

Analyst Expectations for Howmet Aerospace’s Future

FDA Approves First Redosable Gene Therapy, Krystal Biotech’s Treatment For Skin Blistering Disorder